On March 29, the "Li Heart Traditional Chinese Medicine Research and Innovation Fund 2024" project, sponsored by Tianjin Tasly Pharmaceutical Group Co., Ltd. and hosted by the Oriental Hua Xia Cardiovascular Health Research Institute in Suzhou Industrial Park, was officially launched. This initiative aims to support research in cardiovascular medicine and related disciplines by providing funding for research projects and academic training to physicians. Its goal is to explore the clinical efficacy of traditional Chinese medicine in treating cardiovascular diseases, enrich clinical data, and effectively promote the development of traditional Chinese medicine in the field of cardiovascular disease treatment.
Launch Event Scene (Image Provided by Organizer)
Professor Huo Yong from Peking University First Hospital pointed out that cardiovascular disease ranks first among the top ten causes of death in China, and the mortality rate is still increasing year by year. Cardiovascular disease has always been a major public health issue threatening the lives and health of the Chinese people. In recent years, significant progress has been made in the standardized diagnosis and treatment of cardiovascular diseases with traditional Chinese medicine (TCM), and intervention therapies have become more diverse and refined. Although evidence-based medicine for TCM in the treatment of cardiovascular diseases has been emphasized, there are still issues such as insufficient evidence, limited number of high-quality clinical studies, and the need to enhance the academic influence of TCM in the treatment of cardiovascular diseases.
According to Wang Yi, Senior Manager of the Medical Department at the Oriental Huaxia Cardiovascular Health Research Institute in Suzhou Industrial Park, the project plans to fund 15 clinical research topics, with research directions mainly focused on Chinese patent medicine for the treatment of preserved ejection fraction heart failure, cardio-renal metabolic diseases, biventricular diseases, heart damage caused by tumor-related treatments, and specific treatments for elderly cardiovascular disease populations, as well as exploratory research on clinical applications. Each topic will be sponsored with 100,000 to 200,000 CNY.
